Otorhinolaryngology

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on: 
Tuesday, February 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points: 
  • COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
  • To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
  • By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
  • Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on: 
Tuesday, February 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points: 
  • COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
  • To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
  • By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
  • Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Elevate ENT partners with Bob Glazer as Advisor to Prioritize Physician Recruiting Efforts

Retrieved on: 
Tuesday, January 23, 2024

Elevate ENT Partners (“Elevate”), a leading management service organization of ear, nose, and throat (“ENT”) practices nationwide, is pleased to announce the strategic partnership with Bob Glazer, founder of Glazer Business Advisors, to support physician recruiting initiatives.

Key Points: 
  • Elevate ENT Partners (“Elevate”), a leading management service organization of ear, nose, and throat (“ENT”) practices nationwide, is pleased to announce the strategic partnership with Bob Glazer, founder of Glazer Business Advisors, to support physician recruiting initiatives.
  • Throughout his 45-year career, Glazer held pivotal leadership roles shaping the ENT healthcare industry and brings a wealth of expertise to provide unparalleled business consultative services.
  • “In a nutshell, Elevate ENT is where passion meets purpose, and where every physician, regardless of experience, can find a home for growth and success.
  • Elevate ENT is more than a workplace; with a competitive compensation and physician led model, it is a growth hub for otolaryngologists across the nation.

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

Retrieved on: 
Monday, January 22, 2024

PLYMOUTH MEETING, Pa., Jan. 22, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat on the potential treatment of Recurrent Respiratory Papillomatosis (RRP). INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner, will be joined by Dr. Simon Best, Otolaryngologist at Johns Hopkins University and a Principal Investigator in INOVIO's Phase 1/2 trial with INO-3107.

Key Points: 
  • The fireside chat, titled "RRP - Disease Treatment Dynamics & Urgent Need for Therapeutic Modalities," will take place on Wednesday, January 24, 2024, at 12:00pm ET.
  • Hartaj Singh, MBA, Managing Director of Biotechnology Equity Research at Oppenheimer & Co. Inc., will moderate the discussion.
  • He is a fellowship-trained laryngeal surgeon whose clinical interests are focused on voice and airway disorders, with a particular interest in RRP.
  • Prior to joining INOVIO, she was the CEO at Aeras, a not-for-profit organization dedicated to developing new vaccines against tuberculosis (TB).

THE AMERICAN ACADEMY OF COSMETIC SURGERY (AACS) MARKS ITS 40th ANNIVERSARY WITH A COMPREHENSIVE SCIENTIFIC MEETING, PRE-MEETING WORKSHOP, AND DIVERSE OFFERINGS

Retrieved on: 
Tuesday, January 16, 2024

CHICAGO, Jan. 16, 2024 /PRNewswire/ -- The American Academy of Cosmetic Surgery (AACS), the world's largest multi-specialty home for physicians dedicated to cosmetic surgery and aesthetic medicine, will present its 40th Annual Scientific Meeting (ASM) on February 22-24, 2024, with an optional pre-meeting workshop on Ultrasound for Safe Brazilian Butt Lift Surgery and More, on Wednesday, February 21.

Key Points: 
  • In celebration of the AACS' 40th Annual Scientific Meeting, and the 40-year anniversary of the formation of the Academy and its official publication, The American Journal of Cosmetic Surgery, the meeting includes a comprehensive scientific program, as well as an array of advocacy, enrichment, networking and 40th anniversary celebratory activities.
  • Offering 41 educational sessions , the 2024 AACS ASM features foremost experts spanning diverse background specialties, such as dermatology, otolaryngology, general surgery, oral, and maxillofacial surgery, ophthalmology, and plastic and reconstructive surgery.
  • J. Kevin Duplechain, MD, FAACS, cosmetic surgeon and Immediate Past-President of the AACS and Cosmetic Surgery Foundation, will deliver the prestigious Webster Lecture on Friday, February 23.
  • Cosmetic surgery practitioners may register here for the 2024 AACS ASM.

Nearly 100 Physicians from MemorialCare's Long Beach Medical Center, Miller Children's & Women's Hospital Long Beach Recognized by Leading Doctor's Report

Retrieved on: 
Wednesday, January 3, 2024

LONG BEACH, Calif., Jan. 3, 2024 /PRNewswire/ -- MemorialCare's Long Beach Medical Center and Miller Children's & Women's Hospital Long Beach had 86 physicians named Super Doctors and 11 as Rising Stars by the 2023 Southern California Super Doctors & Rising Stars report The Southern California Super Doctors report lists the most outstanding doctors for more than 40 medical specialties, most of whom are in the top 5% of physicians.

Key Points: 
  • LONG BEACH, Calif., Jan. 3, 2024 /PRNewswire/ -- MemorialCare's Long Beach Medical Center and Miller Children's & Women's Hospital Long Beach had 86 physicians named Super Doctors and 11 as Rising Stars by the 2023 Southern California Super Doctors & Rising Stars report The Southern California Super Doctors report lists the most outstanding doctors for more than 40 medical specialties, most of whom are in the top 5% of physicians.
  • The 2023 Southern California Super Doctors report recognizes the top five percent of active doctors in Los Angeles County with two lists: Super Doctors 2023 and Rising Stars.
  • "Having our physicians listed in the Super Doctors and Rising Stars reports highlight the professionalism of our physicians who have attained a high degree of peer recognition and professional achievement," says Joe Kim, M.D., chief medical officer, MemorialCare Long Beach Medical Center.
  • "Our physicians consistently offer exceptional, quality-driven, family-centered care to our patients and families," says Graham Tse, M.D., chief medical officer, MemorialCare Miller Children's & Women's Hospital Long Beach.

ENT and Allergy Associates, LLP Strengthens Commitment to Excellence Welcomes Otolaryngologist Guy Talmor, M.D. to West Nyack, NY Office

Retrieved on: 
Thursday, December 21, 2023

With this goal in mind, ENTA is pleased to announce the addition of Rutgers-trained otolaryngologist, Guy Talmor, M.D., to its West Nyack, NY clinical site, effective August 1st, 2024.

Key Points: 
  • With this goal in mind, ENTA is pleased to announce the addition of Rutgers-trained otolaryngologist, Guy Talmor, M.D., to its West Nyack, NY clinical site, effective August 1st, 2024.
  • Dr. Talmor earned his Bachelor of Science degree in physiology and neuroscience from the University of California at San Diego.
  • He went on to receive his medical degree from the prestigious Keck School of Medicine of University of Southern California, graduating summa cum laude.
  • Dr. Talmor will complete his ENT residency at Rutgers New Jersey Medical School in June 2024.

ENT and Allergy Associates, LLP Continues to Add Talented Physicians Welcomes Otolaryngologist Monica Christine Azmy, M.D. to its Old Bridge, NJ Office

Retrieved on: 
Monday, November 13, 2023

To achieve this objective, significant effort is made to seek out and attract top-tier talent trained at the nation’s leading institutions.

Key Points: 
  • To achieve this objective, significant effort is made to seek out and attract top-tier talent trained at the nation’s leading institutions.
  • This continues with Monica Christine Azmy, M.D., who is the latest recruit to join the group's 240+ board-certified physicians.
  • Dr. Azmy will begin seeing patients at ENTA’s Old Bridge, NJ office effective October 1, 2024.
  • To learn more about ENTA, find a local office or book an appointment, visit www.entandallergy.com or call 1-855-ENTA-DOC.

Preceptis Medical Expands Access to the Hummingbird® Tympanostomy Tube System (TTS) through Medicaid Insurer Pilot Program

Retrieved on: 
Thursday, December 7, 2023

With one million children undergoing OR-based ear tube procedures annually,1 the pilot program shows promise to increase care access and address current health equity challenges encountered by Medicaid populations.

Key Points: 
  • With one million children undergoing OR-based ear tube procedures annually,1 the pilot program shows promise to increase care access and address current health equity challenges encountered by Medicaid populations.
  • Utilizing Preceptis Medical’s patented One-Pass® technology, ENT surgeons make an incision and deliver, position and place ear tubes with a single pass device in-office.
  • “The pilot program serves as a critical step in not only increasing healthcare access, but also in expanding coverage and commercial growth initiatives,” Mielke concluded.
  • To locate a Hummingbird provider, or to learn more about Preceptis Medical’s innovative technology, please visit.

Aerin Medical Announces Sustained Clinical and Quality-of-Life Improvements Two Years After Chronic Rhinitis Treatment with RhinAer®

Retrieved on: 
Tuesday, December 5, 2023

RELIEF demonstrated that a single procedure with RhinAer®, a temperature-controlled, radiofrequency technology, resulted in sustained improvements in chronic rhinitis symptoms, including post-nasal drip and chronic cough, and quality of life through two years along with a substantial decrease in chronic rhinitis medication usage.

Key Points: 
  • RELIEF demonstrated that a single procedure with RhinAer®, a temperature-controlled, radiofrequency technology, resulted in sustained improvements in chronic rhinitis symptoms, including post-nasal drip and chronic cough, and quality of life through two years along with a substantial decrease in chronic rhinitis medication usage.
  • View the full release here: https://www.businesswire.com/news/home/20231205015241/en/
    Two-year results of the RELIEF clinical trial published in The Laryngoscope confirm that a single procedure with RhinAer® resulted in sustained improvements in chronic rhinitis symptoms and quality of life, along with a substantial decrease in chronic rhinitis medication usage.
  • RhinAer, a non-invasive technology developed by Aerin Medical Inc., uses temperature-controlled, radiofrequency energy to provide relief from chronic rhinitis.
  • ENTs use RhinAer as a non-invasive alternative to surgical interventions to directly interrupt nerve signals and help reduce chronic rhinitis symptoms.